Drug Profile
Oncolytic virus - Vyriad
Alternative Names: vesicular stomatitis virus - Vyriad; VSV oncolytic virus - VyriadLatest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator Omnis Pharma
- Developer Mayo Clinic; Vyriad
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Liver cancer; Liver metastases
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for phase-I development in liver cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Liver metastases in USA (Parenteral)